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Abstract
Thrombospondin (TSP) mediates sickle erythrocyte adhesion to endothelium, but the mechanism remains unknown. Since
TSP is comprised of heterogeneously distinct domains, this adhesion may depend on the interaction of specific regions of
TSP with different cell surface receptors. To examine the mechanisms of interaction of TSP with human umbilical vein
endothelial cells (HUVEC), we performed binding studies using soluble [125I]TSP. Our data showed that (i) monoclonal
antibodies (MoAbs) against cell surface heparan sulfate (HS) or the heparin-binding domain of TSP, or cleavage of HS on
HUVEC by heparitinase reduced TSP binding by 28^40%, (ii) the RGD peptide or MoAbs against integrin KvL3 or the
calcium binding region of TSP inhibited binding by 18^28%, and (iii) a MoAb against the cell-binding domain of TSP
inhibited binding by 36%. Unmodified heparin inhibited the binding of TSP to endothelial cells by 70% and did so far more
effectively than selectively desulfated heparins, HS or chondroitin sulfate. Heparin inhibited TSP binding to HUVEC at
much lower concentrations than were required to inhibit TSP binding to sickle erythrocytes. Unmodified heparin effectively
inhibited the TSP-mediated adhesion of sickle erythrocytes to HUVEC. These data imply that cell surface HS-mediated
mechanisms play a key role in TSP-mediated sickle erythrocyte adhesion to endothelium, and heparin may be of use for
inhibition of this adhesion. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
In sickle cell disease sickle erythrocytes adhere
strongly to endothelium [1], a phenomenon mediated
by speci¢c interactions between sickle erythrocytes
and endothelial cell receptors and plasma proteins,
such as thrombospondin (TSP), von Willebrand fac-
tor, ¢brinogen and ¢bronectin [2^4]. Earlier studies
from our laboratory and others showed that TSP
present in the plasma augments sickle erythrocyte
adhesion to cultured endothelial cells in vitro [3^5]
and that plasma levels of TSP are increased in the
patients with sickle cell disease [6]. Nevertheless, the
role of TSP as an adhesion molecule and the mech-
anism of TSP^vascular endothelial cell interaction
still remain incompletely de¢ned.
Interactions involving TSP, endothelial cells and
erythrocytes are likely to be complex, since TSP, a
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450 kDa glycoprotein, is comprised of several heter-
ogeneous domains. Interactions of these domains
with di¡erent molecules and cell surface receptors
mediate the diverse biologic functions of TSP includ-
ing cell adhesion and migration, platelet aggregation,
apoptosis and modulation of angiogenesis [7^15].
The N-terminal domain of TSP contains clusters of
basic amino acid residues that bind to heparan sul-
fate proteoglycans (HSPG), sulfatides and low-den-
sity lipoprotein receptor-related protein [16^18]. The
type 1 repeats containing the CSVTCG sequence
binds the transmembrane glycoprotein CD36 [19].
The RGD sequence in the last type 3 repeat may
mediate TSP interactions with several integrins [20^
22]. The C-terminal cell-binding domain interacts
with a 52 kDa integrin-associated protein (IAP) [23].
To elucidate the mechanism of action of TSP in
pathophysiological conditions including sickle cell
disease, it is of primary importance to understand
the speci¢c interactions of TSP with the cell types
involved such as endothelial cells and erythrocytes.
Data available on the exact mechanisms and the rel-
ative contributions of TSP^EC interactions are con-
£icting. For example, TSP promotes human umbil-
ical vein endothelial cell (HUVEC) migration via
interactions with IAP and the integrin receptor
KvL3 [23], and cell adhesion experiments suggest
that the attachment of human endothelial cells to
immobilized TSP is integrin-mediated [20]. On the
other hand, direct binding studies performed on
non-human (bovine and porcine) endothelial cells
demonstrate that TSP binds almost exclusively to
heparan sulfate (HS) [16,24]. Previous studies deter-
mined TSP interaction with human endothelial cells
and sickle erythrocytes by measuring the adhesion of
cells in suspension to immobilized TSP [22,25]. How-
ever, since endothelial cells in suspension lose their
normal morphology and undergo apoptosis [26,27],
the interactions of endothelial cells in suspension
may be altered and these cells may exhibit binding
sites that are normally masked on cells in monolayers
[16]. Conversely, immobilized TSP can achieve cell-
binding conformation not exhibited by soluble TSP,
as exempli¢ed by the inability of soluble TSP to
block sickle erythrocyte adhesion to immobilized
TSP [28]. Thus, the nature of interactions between
TSP and endothelial cell surface molecules is unclear,
especially for human endothelial cells.
To de¢ne the role of TSP in sickle cell disease we
performed direct binding studies of soluble [125I]TSP
to HUVEC monolayers and to sickle erythrocytes.
Endothelial cell surface HS-mediated binding ap-
pears to contribute maximally to TSP^EC interac-
tion. We therefore investigated HS-mediated mecha-
nisms in detail using selectively desulfated heparins
and other glycosaminoglycans (GAGs), in addition
to other possible mechanisms of TSP^EC interaction.
We also examined the ability of di¡erent GAGs to
modulate the interaction of TSP with sickle erythro-
cytes. We hypothesized that inhibition of this binding
may prevent TSP-mediated sickle erythrocyte adhe-
sion to endothelium. This study shows that EC sur-
face HS-mediated mechanisms are involved in the
TSP-mediated sickle erythrocyte adhesion to endo-
thelial cells, and that heparin inhibits this abnormal
adhesion.
2. Materials and methods
2.1. Reagents
Peptides CSVTCG, VGCSTC and MAL III
(SPWDICSVTCGGVQKRSK, but with the cys-
teines replaced by alanine) were synthesized by the
Microchemical Facility, University of Minnesota;
RGDS and RGES were from Sigma, St. Louis,
MO. Monoclonal antibodies (MoAbs) were obtained
as follows: OKM5 (anti-CD36) from Ortho Diag-
nostics Systems, Raritan, NJ; LM609 (anti-KvL3)
from Chemicon, Temecula, CA; Hep SS-1 (anti-
HS) from Seikagaku America, Rockville, MD;
A4.1, D4.6 and C6.7 (against the type I region,
type III region/calcium binding domain and car-
boxy-terminal domain, respectively, of the TSP mol-
ecule) from NeoMarkers, Fremont, CA; and TSP
N-1 (against the N-terminal region of TSP), a kind
gift from Dr. Cheryl A. Hillery, Medical College of
Wisconsin, Milwaukee, WI. Control MoAbs and
mouse ascites £uid (clone NS-1) were obtained
from Sigma. Heparitinase (heparitin sulfate elimi-
nase, EC 4.2.2.8, from Flavobacterium heparinum)
was from ICN Biomedicals, Aurora, OH. Chon-
droitin ABC lyase (EC 4.2.2.4, from Proteus vulgaris)
and di¡erentially chemically desulfated heparins were
from Seikagaku America. Other chemicals were from
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Sigma, and tissue culture reagents from Gibco BRL,
Gaithersburg, MD. The chondroitin sulfate (CS)
used to block TSP binding to HUVEC (Fig. 3) and
to erythrocytes (Fig. 7) was chondroitin sulfate A.
2.2. Endothelial cell culture
HUVEC were cultured from umbilical cords as
described [29]. Cells were grown in medium 199 con-
taining 10% fetal bovine serum, penicillin (100 U/ml),
streptomycin (100 U/ml), L-glutamine (0.2 mM), so-
dium pyruvate (1 mM), heparin (0.004%) and 0.1
mg/ml endothelial cell growth supplement (Vec Tec,
Schanectady, NY). Cells were split 1:4 every 7 days
and experiments were performed on cells between
passages 2 and 3. All experiments were done using
con£uent cell monolayers in 24-well plates. At con-
£uence, the cell number in representative wells was
determined using a hemocytometer.
2.3. Preparation of TSP
TSP was puri¢ed from fresh human platelets, as
described earlier [30]. Brie£y, TSP was released
from platelets using thrombin. Releasate was sub-
jected to heparin^agarose a⁄nity chromatography
and TSP eluted from the column using 0.55 mol/l
NaCl in Tris^HCl (0.01 mol/l, pH 7.4) containing
0.3 mmol/l calcium chloride. The TSP-containing
fraction was size fractionated using BioRad A 0.5 m
gel. TSP was recovered in the void volume of the
column. Homogeneity of the protein was con¢rmed
by SDS^PAGE followed by silver staining.
2.4. Iodination of TSP
TSP was iodinated with Na 125I (NEN, Boston,
MA) using Iodobeads (Pierce, Rockford, IL) [31].
Brie£y, TSP and Na 125I were allowed to react with
Iodobeads for 15 min at room temperature. Labeled
TSP was separated from unconjugated 125I on a Se-
phadex G-50 column. Fractions containing TSP were
dialyzed to remove free 125I. The speci¢c activity of
iodinated TSP was approximately 550 WCi/mg pro-
tein. The integrity of the intact iodinated protein was
con¢rmed by polyacrylamide gel electrophoresis
under reducing conditions, followed by autoradiog-
raphy.
2.5. TSP binding to HUVEC
Binding medium contained medium 199 with 0.5%
bovine serum albumin (BSA) and 1 mmol/l calcium
chloride. Con£uent HUVEC monolayers in 24-well
plates were incubated for speci¢c time periods as
required for the experiments at 4‡C with 1 Wg/ml
[125I]TSP, in the presence or absence of heparin (10
Wg/ml, corresponding to 1.75 USP U/ml) and/or oth-
er molecules (antibodies, peptides and GAGs) as in-
dicated in Section 3 and ¢gure legends. After incu-
bation, the monolayers were washed three times with
cold Hank’s balanced salt solution (HBSS) without
calcium, and cells were lifted using trypsin. The wells
were washed and washings added to the respective
fractions. Radioactivity was counted in a gamma
counter. Isotype matched control antibodies and
control peptides were used for all experiments.
Enzyme treatment of HUVEC with heparitinase or
chondroitin ABC lyase was performed as described
in the legend to Fig. 2. Enzymes inactivated by boil-
ing at 100‡C for 10 min were used as controls.
2.6. 2-O-Desulfation of heparins
Unmodi¢ed heparin or O-sulfated heparin were
dissolved in dH2O (4 mg/ml) and the pH was ad-
justed to 12.5 using 0.1 N NaOH [32]. The solution
was frozen, lyophilized and then rehydrated in the
original volume of dH2O, and dialyzed against
water.
2.7. TSP binding to erythrocytes
Normal and sickle (homozygous) volunteer donors
provided whole blood in citrated vacutainer tubes
(acid citrated dextrose solution A; Becton Dickinson,
Lincoln Park, NJ). Erythrocytes were washed twice
with HBSS containing 1 mmol/l calcium and 1%
BSA (HBSS/calcium/BSA). Sickle erythrocytes were
pre-incubated with 10 Wg/ml unlabeled TSP for 30
min to block non-speci¢c binding and washed with
HBSS/calcium/BSA. Erythrocytes (106 cells/100 Wl
HBSS/calcium/BSA) were incubated with 1 Wg/ml
[125I]TSP and GAGs (as indicated in the legend to
Fig. 7) at 4‡C for 1 h. [125I]TSP and GAGs were
added simultaneously to the erythrocytes, using two
separate pipettes. In initial experiments, we had ob-
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served that the maximal amount of TSP bound to
sickle erythrocytes at 1 h (data not shown). Follow-
ing the incubation, the cell suspension was layered on
silicon oil and centrifuged. After aspirating the
supernatant, the cell pellet was collected by amputat-
ing the tip of the microfuge tube and counted in a
gamma counter.
2.8. Adhesion assay
Erythrocytes were suspended to a hematocrit of
2.5% in the desired suspension medium: (i) HBSS/2
mmol/l calcium/0.5% BSA, or (ii) autologous citrated
platelet poor plasma obtained from freshly drawn
blood samples by centrifugation at 21 600Ug for 15
min. The adhesion assay was performed as described
previously [3]. Brie£y, the erythrocyte suspension was
layered on a con£uent HUVEC monolayer (in a 96-
well tissue culture plate) that had been washed three
times with HBSS/BSA, and incubated for 40 min at
37‡C in a humidi¢ed chamber. Addition of potential
e¡ector molecules (as indicated in the legend to Fig.
8) was made directly to the erythrocyte suspension
immediately before layering on the HUVEC mono-
layers. To remove non-adherent erythrocytes, plates
were sealed using an adhesive ¢lm and inverted for
an additional 30 min at 37‡C, and the adhesive ¢lm
removed while keeping the plates inverted. Percent of
adherent erythrocytes was determined by measuring
the hemoglobin concentration using a Thermo-max
kinetic microplate reader (Molecular Devices, Menlo
Park, CA). Adherence was expressed as the percent
of erythrocytes adhering to HUVEC, which was de-
rived from the total hemoglobin applied to the wells,
with correction for absorbance from wells containing
HUVEC but no added erythrocytes.
2.9. Statistics
Data are expressed as mean þ S.E.M. Levels of
signi¢cance were determined by paired or unpaired
Students’ t-test, as appropriate.
3. Results
The binding of TSP was studied both in the ab-
sence of heparin (total binding) and in the presence
of 10 Wg/ml heparin. Heparin inhibitable binding
(HIB), the di¡erence between the binding of
[125I]TSP in the absence and presence of heparin,
has been assumed to represent speci¢c binding, while
binding that cannot be inhibited with heparin (non-
HIB) has been assumed to be non-speci¢c [16,24]. In
our studies, heparin inhibited the binding of
[125I]TSP to HUVEC by 67 þ 6.7%. Results are ex-
pressed and compared as total binding.
3.1. TSP binding to HUVEC
Binding of [125I]TSP to HUVEC at 4‡C increased
consistently for the ¢rst 2 h and thereafter remained
constant for 6 h (Fig. 1). A similar time course was
observed for both HIB and non-HIB.
3.2. TSP binds to cell surface heparan sulfate on
HUVEC
As shown in Fig. 2, the total binding of TSP to
HUVEC was reduced: (i) by 36% upon removal of
the cell surface HS using heparitinase; (ii) by 28% in
the presence of a MoAb (Hep SS-1) to cell surface
HS; (iii) by 40% in the presence of a neutralizing
MoAb (TSP N-1) to the heparin binding domain of
TSP; and (iv) by 67% in the presence of 10 Wg/ml
Fig. 1. Time course of TSP binding to HUVEC. The binding
assay was performed on con£uent cell monolayers (approxi-
mately 105 cells/well in 24-well clusters) as described in Section
2. HUVEC were incubated with 1 Wg/ml [125I]TSP in the pres-
ence or absence of 10 Wg/ml heparin at 4‡C for the indicated
time periods and the bound radioactivity determined. Heparin-
inhibitable binding of TSP (a) was calculated by subtracting
the binding in the presence of 10 Wg/ml of heparin (R) from
the binding in the absence of heparin (b). Each value was ob-
tained from the mean of three separate experiments.
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soluble heparin. In contrast, non-HIB of TSP (i.e.,
persisting in the presence of heparin) was not a¡ected
by prior treatment of HUVEC by heparitinase or in
the presence of either MoAb (results not shown).
Enzymatic removal of the cell surface CS did not
alter the binding of [125I]TSP. No signi¢cant inhibi-
tion of TSP binding was observed in control experi-
ments using HUVEC incubated with enzymes that
had been inactivated by boiling for 10 min, or iso-
type matched control antibodies, or control ascitic
£uid (data not shown). That inhibition of TSP bind-
ing in presence of the anti-HS MoAb was lower than
after enzymatic removal of HS or in presence of a
MoAb against the heparin binding domain of TSP
may be due to the inability of the anti-HS MoAb to
completely block cell surface HS, which are hetero-
geneous molecules. These data indicate that about
one-third of TSP binding to HUVEC is accounted
for by interaction of the N-terminal region with en-
dothelial cell HS.
3.3. Soluble glycosaminoglycans interfere with TSP
binding to HUVEC in a dose-dependent manner
We studied the binding of [125I]TSP to HUVEC in
the presence of di¡erent concentrations of soluble
heparin, HS and CS. Maximal inhibition of binding
was achieved by 0.1 Wg/ml of heparin and by 10 Wg/
ml of HS (Fig. 3). At each concentration, inhibition
of binding by CS was lower than that by heparin or
HS. These data demonstrate that heparin, the most
highly sulfated GAG, is the most e¡ective inhibitor
of TSP binding to HUVEC.
3.4. Sulfation of glycosaminoglycans is a determining
factor in TSP^HUVEC interactions
To examine if sulfation of GAGs at speci¢c posi-
tions in£uences the interaction of TSP with endothe-
lial cells, we studied the e¡ect of selectively desul-
fated heparins on the binding of [125I]TSP to
HUVEC. As shown in Fig. 4, heparins desulfated
at one or two positions (2-O- and/or N-desulfated
heparins) inhibited TSP binding to a much lesser
extent than unmodi¢ed, highly sulfated heparin. In
contrast, completely desulfated heparin, even up to a
concentration of 100 Wg/ml, did not inhibit TSP
binding at all. Taken together with the data in Fig.
3, these results indicate that the e⁄cacy of GAGs to
modulate the binding of TSP to HUVEC is depend-
ent on the extent of sulfation of GAGs, rather than
on a speci¢c pattern of sulfation.
Fig. 2. Cell surface HS mediate TSP binding to HUVEC. The
binding assay was performed as described in Section 2, on HU-
VEC monolayers treated with heparitinase (10 mU/ml for 3 h
at 37‡C) or chondroitin ABC lyase (25 mU/ml for 3 h at
37‡C), or in the presence of MoAbs against HS (Hep SS-1, 10
Wg/ml) or against the N-terminal heparin-binding domain
(HBD) of TSP (TSP N-1, 10 Wg/ml). Comparison between con-
trol (total [125I]TSP bound in the absence of heparin) and other
conditions: *P6 0.001. n = 3 experiments.
Fig. 3. Soluble glycosaminoglycans inhibit TSP binding to HU-
VEC in a dose-dependent manner. The binding assay was per-
formed as described in Section 2, in the presence of increasing
concentration of the inhibitors (heparin (solid bars), HS (open
bars), or CS (hatched bars)) for 2 h at 4‡C. Data are shown as
percent of control (total [125I]TSP bound in the absence of in-
hibitors, broken line). Comparison between control and other
conditions: *P6 0.05, 3P6 0.01, 4P6 0.005, **P6 0.001. n = 3
experiments.
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3.5. TSP binds to the cell surface integrin receptor
KvL3 independent of cell surface
glycosaminoglycans
We next examined if TSP binds to HUVEC via
speci¢c interaction of additional domains of TSP
with cell surface receptors other than GAGs. As
shown in Fig. 5A, the total binding of TSP to HU-
VEC was reduced (i) by 27% in the presence of the
KvL3 blocking MoAb LM609 (ii) by 28% in the pres-
ence of soluble RGDS peptide (iii) by 18% in the
presence of the neutralizing MoAb D4.6, which
binds to an epitope on the calcium binding area
that contains the single RGD sequence of TSP-1
that interacts with the cell surface receptor KvL3
[20]. Moreover, the inhibitory e¡ect of LM609 was
strictly additive (within experimental error) to the
inhibition observed by enzymatic cleavage of the
cell surface HS by heparitinase or in presence of
the blocking MoAb Hep SS-1 against cell surface
HS. The peptide RGDS and MoAb D4.6 further
inhibited the binding of TSP to HUVEC even in
the presence of soluble heparin (Fig. 5B), suggesting
that at least a portion of ‘non-speci¢c’ non-HIB may
be accounted for by identi¢able mechanisms. Isotype
matched control antibodies did not show any signi¢-
cant inhibition in the presence or absence of heparin
as compared to controls in the presence or absence of
heparin, respectively (data not shown). Thus, TSP
binds to cell surface KvL3 via the RGDS sequences
in the type III repeats of TSP, independent of inter-
actions with cell surface HS.
Fig. 5. Integrin receptor KvL3-mediated TSP binding to HU-
VEC. The binding assay was performed using 1 Wg/ml of
[125I]TSP in the presence of 66 Wg/ml of the indicated peptides,
10 Wg/ml of each MoAb, or on heparitinase (Hep’nase)-treated
cells (as described for Fig. 2), in the absence (A) or presence
(B) of heparin. Data are shown as percent of control (total
binding in the absence of heparin). Comparison between (A)
control (total binding of TSP) and other conditions, or (B)
binding in presence of heparin alone and other conditions:
*P6 0.05, 3P6 0.01, **P6 0.005, 4P6 0.001. n = 3^5 experi-
ments.
Fig. 4. E¡ect of sulfation of heparin on TSP binding to HU-
VEC. The binding assay was performed with 1 Wg/ml [125I]TSP
for 2 h at 4‡C in the presence of increasing concentrations of
either unmodi¢ed heparin (solid bars) or selectively desulfated
heparins (completely desulfated (open bars), 2-O-desulfated
(hatched bars), N-desulfated (checkered bars), and 2-O- and N-
desulfated (striped bars) heparins). Comparison between control
(total [125I]TSP bound in the absence of heparin, broken line)
and other conditions: *P6 0.05, 3P6 0.01, 4P6 0.001. n = 3^5
experiments.
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3.6. Involvement of the carboxy terminal domain of
TSP in binding to HUVEC
Recent studies in other cell types have demon-
strated that the carboxy terminal domain of TSP
binds to IAP/CD47 [23,33]. We observed that the
total binding of TSP to HUVEC is inhibited by
36% in presence of the MoAb C6.7 against the car-
boxy terminal domain of TSP 1 (Fig. 5A). The
MoAb C6.7 also signi¢cantly inhibited the binding
of TSP to HUVEC even in the presence of soluble
heparin (Fig. 5B), suggesting an additional mecha-
nism that may exist for the interaction of TSP with
human endothelial cells.
3.7. TSP binding to cell surface CD36
It has been shown earlier that the CSVTCG se-
quence in TSP mediates its binding to the cell surface
receptor CD36[19], and the amino acid residues
downstream from CSVTCG present in the type I
region are also required for CD36-mediated binding
[34,35]. However, the binding of TSP to HUVEC in
the presence or absence of heparin was not inhibited
by the CSVTCG peptide, the MoAb A4.1 which
binds to the type I repeats of TSP, the MAL III
Fig. 6. A model for TSP^HUVEC interaction. Di¡erent regions of TSP interact with speci¢c receptors or cell surface molecules on
HUVEC, as discussed in the text. Broken arrows indicate possible receptor^ligand interactions. The accompanying table shows the
percent inhibition of total binding of TSP in the presence of MoAbs, peptides or enzymatic treatment of HUVEC, indicating the rela-
tive contribution of each TSP region^HUVEC receptor to the binding. Hep’nase, heparitinase treatment of HUVEC; HSPG, HS pro-
teoglycans.
Fig. 7. Soluble GAGs inhibit TSP binding to sickle erythrocytes
in a dose-dependent manner. The binding of 1 Wg/ml [125I]TSP
to sickle erythrocytes was determined in the presence of increas-
ing concentrations of heparin (solid bars), HS (open bars) or
CS (hatched bars). Data are expressed as percent of [125I]TSP
bound to sickle erythrocytes in the absence of GAGs. Compari-
son between TSP control (without any inhibitor, broken line)
and other conditions: *P6 0.05, 3P6 0.005, 4P6 0.001. n = 3^5
experiments.
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peptide, or by the anti-CD36 MoAb OKM5 (Fig. 6).
As observed by us on the HUVEC used in the
present study, as well as observed by others, CD36
is not expressed on cultured HUVEC [29,36].
The combined results of the binding studies sum-
marized in Fig. 6 show that TSP interacts with HU-
VEC by at least three di¡erent mechanisms. Of these,
HS-mediated binding may be the major mechanism
of TSP interaction with HUVEC.
3.8. Heparin inhibits TSP-mediated adhesion of sickle
erythrocytes to endothelial cells
As earlier studies indicated that TSP binds to
sickle erythrocytes via CD36 and/or sulfatides
[3,37], we examined the e¡ect of GAGs on this bind-
ing (Fig. 7). The maximal inhibition of binding of
[125I]TSP to sickle erythrocytes was achieved by hep-
arin (55% inhibition at 100 Wg/ml). Both HS and CS
inhibited binding to a signi¢cantly lesser extent (25%
and 34% inhibition, respectively, at 100 Wg/ml;
P6 0.02 compared with 100 Wg/ml heparin).
Previous studies from our laboratory have also
demonstrated that TSP mediates the adhesion of
sickle erythrocytes to HUVEC [3]. We found that
heparin signi¢cantly reduced the TSP-mediated sickle
erythrocyte adhesion to HUVEC in serum-free con-
ditions (Fig. 8A; P6 0.05). In vivo, high concentra-
tions of TSP in the plasma of patients with sickle cell
disease [6] and other molecules [38] may in£uence
adhesion. We therefore also examined the e¡ect of
heparin on adhesion in the presence of plasma from
patients with sickle cell disease, since this more accu-
rately represents in vivo conditions. Heparin also in-
hibited sickle erythrocyte adhesion to HUVEC when
tested in the presence of plasma (Fig. 8B).
4. Discussion
We de¢ne the relative contribution of several dif-
ferent receptor^ligand interactions that mediate the
binding of TSP to human endothelial cells (Fig. 6).
The importance of de¢ning these mechanisms lies in
the value of understanding the role of TSP in sickle
erythrocyte adhesion to endothelium. Similar mech-
anisms may also apply to other pathophysiological
conditions. Maximal binding of TSP to HUVEC was
observed at 2 h at 4‡C, which is in agreement with
both porcine and bovine endothelial cells [16,24].
The N-terminal heparin-binding domain of TSP
binds to HS proteoglycans on HUVEC. We observed
that the decrease in TSP binding following hepariti-
nase treatment of HUVEC was comparable to the
decrement caused by MoAbs against the N-terminal
heparin-binding domain of TSP or against cell sur-
face HS (Fig. 6). Soluble heparin, which binds with
high a⁄nity to TSP [39], inhibited a larger propor-
Fig. 8. Heparin inhibits sickle erythrocyte adhesion to HUVEC.
(A) Adhesion of sickle erythrocytes to HUVEC in the presence
or absence of 0.1 USP U/ml heparin and/or 1 Wg/ml TSP, as in-
dicated. (B) Adhesion of normal or sickle erythrocytes to HU-
VEC in the presence of platelet-poor plasma in the presence or
absence of heparin. Data are shown as percent adherence, cal-
culated as described in Section 2. n = 3^6 experiments.
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tion (67%) of TSP binding to HUVEC than hepar-
itinase treatment or the blocking MoAbs. This may
possibly be a consequence of binding of heparin to
di¡erent regions of TSP [40,41], or the induction of a
conformational change in TSP, as has been reported
for other proteins [42,43]. That chondroitinase ABC
treatment of HUVEC did not reduce TSP binding is
consistent with the observation that the majority of
the GAGs on HUVEC are HS [24,44]. Previous stud-
ies of TSP binding to bovine and porcine endothelial
cells indicated that 85^90% binding was HS-medi-
ated; the remaining 10^15% was considered to be
non-speci¢c [16,24]. Our study indicates that TSP
binding to human endothelial cells involves addition-
al binding mechanisms.
Sulfation is a determining factor in the interaction
of TSP with cell surface GAGs [24,40,41]. We dem-
onstrate that inhibition of TSP binding to HUVEC
by GAGs requires a high degree of sulfation. Native
heparin, which is highly sulfated [45], inhibited bind-
ing maximally. Selective desulfation of heparin at the
2-O- and/or N-sulfate positions reduced its capability
to inhibit binding. Completely desulfated heparin
had no inhibitory activity. HS and CS, which are
less sulfated than heparin, inhibited binding to a less-
er extent than heparin. These results are consistent
with previous studies demonstrating that higher con-
centrations of CS are required to inhibit TSP binding
to bovine aortic endothelial cells, as compared to
heparin [16].
In various cell types, the RGD sequence in the
type III repeat of TSP binds to the integrin KvL3
[20,41,46,47], and the cell-binding domain binds to
cell surface IAP [23,33]. Our results indicate that a
signi¢cant proportion of TSP binding to HUVEC is
mediated by RGDS^KvL3 interaction, and via the
cell-binding domain of TSP. Binding was signi¢-
cantly inhibited by MoAbs against KvL3, the RGD-
containing region or the cell-binding domain of TSP,
as well as by the peptide RGDS (Fig. 6). These bind-
ing interactions occur through HS-independent
mechanisms, since the inhibitory e¡ect of MoAb
against KvL3 was additive to the inhibitory e¡ects
of heparitinase treatment or MoAb against cell sur-
face HS. These data best ¢t a model in which HS/
heparin-binding domain and RGD/KvL3 are inde-
pendent and, in fact, mutually exclusive binding in-
teractions. If TSP binding involved cooperative par-
ticipation of both receptors, then the two
mechanisms would be expected to be synergistic
rather than additive. The binding of HUVEC, which
express a high amount of IAP [23], to TSP via the
cell-binding domain may be of additional impor-
tance, since cell-binding domain^IAP interactions
have been suggested to promote secondary activation
of KvL3 [48] and exposure of cryptic RGD sequences
[49]. Our ¢ndings with HUVEC contrast with earlier
studies on non-human endothelial cells, where the
RGD-containing C-terminal region of TSP did not
participate in binding [16,24]. These data on human
endothelial cells reconcile previous TSP binding stud-
ies on animal endothelial cells which suggest that
virtually all binding is via cell surface proteoglycans,
with functional studies indicating that TSP uses oth-
er endothelial cell surface molecules for biologic
functions such as angiogenesis, apoptosis and cell
attachment. However, of various mechanisms, inter-
action via cell surface HS may be contributing max-
imally to TSP^EC interactions.
In addition to binding to endothelial cells, TSP
bound to sickle erythrocytes. As for HUVEC, TSP
binding to sickle erythrocytes was inhibited in a
dose-dependent manner by heparin, HS and CS,
and the maximal inhibition was seen with heparin.
There was no signi¢cant di¡erence between the in-
hibition by heparin or HS or CS at all the concen-
trations except 100 Wg/ml. However, in striking con-
trast to dose response of inhibition of TSP binding to
HUVEC, a 3-log higher concentration of heparin
was required for 50% inhibition of TSP binding to
sickle erythrocytes.
The potential biologic signi¢cance of TSP binding
to HUVEC and to sickle erythrocytes is underscored
by the ability of heparin to inhibit TSP-mediated
sickle erythrocyte adhesion to human endothelial
cells. This inhibitory activity of heparin is likely
due to inhibition of TSP binding to HUVEC, as
the adhesion of sickle erythrocytes to HUVEC was
inhibited by a lower concentration of heparin than is
required for inhibition of TSP binding to sickle er-
ythrocytes. Other studies have shown that adhesion
of sickle erythrocytes to immobilized TSP is not in-
hibited by heparin [28,37]. Our study suggests hepa-
rin is more likely to a¡ect TSP^endothelial cell inter-
actions rather than TSP^erythrocyte binding, and
suggest that heparin may be useful for pharmacolog-
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ical modulation of abnormal adhesion of sickle ery-
throcytes to the endothelium. This paper provides
insight into the mechanism and prevention of TSP-
mediated sickle cell adhesion to human endothelial
cells and may be the basis for investigating the pos-
sible prevention of abnormal adhesion of sickle er-
ythrocytes to endothelium in more advanced shear-
£ow adhesion models, and subsequently for clinical
trials.
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